Nov 21, 2022

Featuring an interview with Professor Arndt Vogel, including the following topics:

• Case: A man in his early 40s with hepatitis B virus infection and hepatocellular carcinoma (HCC) with Child-Pugh C, ALBI 3 cirrhosis (0:00)
• Case: A man in his late 60s with metastatic HCC with Child-Pugh A, ALBI 2 cirrhosis (7:54)
• Case: A man in his early 70s with rheumatoid arthritis diagnosed with Barcelona Clinic Liver Cancer Stage 2 HCC (10:54)
• The etiology of HCC and response to immunotherapy (13:20)
• Evaluating recent first-line Phase III combination trials for unresectable HCC (19:57)
• Managing treatment-emergent adverse events with combination therapies for advanced HCC (25:47)
• Potential long-term benefits of immunotherapy-based treatments (29:33)
• Impact of recent changes in HCC treatment algorithms on the use of local therapy (31:46)
• Use of neoadjuvant therapy to convert unresectable HCC to resectable disease (37:00)
• Using tyrosine kinase inhibitors for patients with HCC and comorbidities (44:22)

CME information and select publications